Zacks Research Issues Optimistic Forecast for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Zacks Research upped their Q1 2025 earnings estimates for Axsome Therapeutics in a report released on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.33) per share for the quarter, up from their prior estimate of ($1.77). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.40) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.24) EPS.

AXSM has been the topic of several other reports. Wells Fargo & Company increased their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Robert W. Baird increased their target price on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley increased their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $167.36.

Remove Ads

Axsome Therapeutics Stock Performance

NASDAQ AXSM traded down $0.92 during mid-day trading on Friday, reaching $124.76. 357,815 shares of the stock were exchanged, compared to its average volume of 644,908. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company has a market capitalization of $6.08 billion, a P/E ratio of -20.83 and a beta of 1.00. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The business's 50 day moving average is $113.06 and its 200-day moving average is $99.22.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $2,599,000. PDT Partners LLC acquired a new stake in Axsome Therapeutics during the third quarter worth approximately $1,052,000. Pallas Capital Advisors LLC acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $2,237,000. Finally, Aigen Investment Management LP acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $395,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.